Isolation of LEM domain-containing 1, a novel testis-specific gene expressed in colorectal cancers

Daisuke Yuki1, Yu-Min Lin, Yoshitaka Fujii

  • 1Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108-8639, Japan.

Oncology Reports
|July 16, 2004
PubMed

Insights

Researchers identified a novel gene, LEMD1, highly expressed in colorectal carcinoma (CRC) tumors but not normal tissues. This finding suggests LEMD1 as a potential target for CRC diagnosis and immunotherapy.

Area of Science:

  • Genomics
  • Molecular Biology
  • Oncology

Background:

  • Colorectal carcinoma (CRC) presents a significant health burden, necessitating novel diagnostic and therapeutic targets.
  • Genome-wide expression profiling is a powerful tool for identifying genes implicated in cancer development.

Purpose of the Study:

  • To identify novel molecular targets for the diagnosis, treatment, and prevention of colorectal carcinoma (CRC).
  • To investigate the expression patterns of LEMD1 in CRC and normal tissues.

Main Methods:

  • Genome-wide expression profiling using a cDNA microarray with 23,040 human genes.
  • Northern blotting to analyze LEMD1 expression in various normal adult tissues and CRC samples.
  • Analysis of alternative splicing variants of LEMD1 transcripts.

Main Results:

  • A novel gene, LEM domain-containing 1 (LEMD1), was identified with significantly elevated expression in 17 out of 18 CRC samples compared to non-cancerous mucosa.
  • LEMD1 expression was predominantly observed in the testis among 16 normal adult tissues examined.
  • A specific alternatively spliced transcript of LEMD1 (656 nucleotides) was found to be expressed in CRCs.

Conclusions:

  • LEMD1 is frequently transactivated in colorectal tumors and exhibits restricted expression in normal tissues, primarily the testis.
  • The LEMD1 protein is classified as a cancer-testis antigen (CTA).
  • LEMD1 represents a promising target antigen for the development of novel immunotherapies for colorectal carcinoma.

Related Concept Videos

Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Pleiotropy01:33

Pleiotropy

Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...